Table 2.

Comparison of recurrent versus newly diagnosed GBM tumors using the Nanostring Pan-Cancer Immune panel. All patients were Dex-naïve at the time of surgery. Of 770 genes on the panel, 527 had average raw counts greater than 50. Eight of these genes have a p-value less than 0.05 and fold change greater than 2. All 8 show loss of mRNA expression in recurrent tumors.

Gene Name	Accession #	Fold Change Recurrent vs Newly Diagnosed	P value	Function
CHIT1	NM_003465.2	−2.23	0.001	Innate Immune Response
TLR2	NM_003264.3	−2.3	0.028	Pro-inflammatory
MR1	NM_001531.2	−2.36	0.045	Antigen Presentation
THY1	NM_006288.2	−3.95	0.026	Immune Regulation
CFB	NM_001710.5	−4	0.029	Innate Immune Response
SAA1	NM_199161.1	−6.93	0.046	Innate Immune Response
CFI	NM_000204.3	−7.91	0.021	Pro-inflammatory
HAMP	NM_021175.2	−31.28	0.026	Innate Immune Response